- Home
- ETON vs CRBU Comparison
ETON vs CRBU Comparison
Compare ETON & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- CRBU
- Stock Information
- Founded
- ETON 2017
- CRBU 2011
- Country
- ETON United States
- CRBU United States
- Employees
- ETON N/A
- CRBU N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ETON Health Care
- CRBU Health Care
- Exchange
- ETON Nasdaq
- CRBU Nasdaq
- Market Cap
- ETON 199.5M
- CRBU 236.3M
- IPO Year
- ETON 2018
- CRBU 2021
- Fundamental
- Price
- ETON $12.44
- CRBU $1.84
- Analyst Decision
- ETON Strong Buy
- CRBU Strong Buy
- Analyst Count
- ETON 2
- CRBU 4
- Target Price
- ETON $15.00
- CRBU $12.00
- AVG Volume (30 Days)
- ETON 242.8K
- CRBU 1.5M
- Earning Date
- ETON 11-12-2024
- CRBU 11-06-2024
- Dividend Yield
- ETON N/A
- CRBU N/A
- EPS Growth
- ETON N/A
- CRBU N/A
- EPS
- ETON N/A
- CRBU N/A
- Revenue
- ETON $34,677,000.00
- CRBU $11,475,000.00
- Revenue This Year
- ETON $23.05
- CRBU N/A
- Revenue Next Year
- ETON $81.27
- CRBU N/A
- P/E Ratio
- ETON N/A
- CRBU N/A
- Revenue Growth
- ETON 5.64
- CRBU N/A
- 52 Week Low
- ETON $3.03
- CRBU $1.50
- 52 Week High
- ETON $13.98
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- ETON 65.21
- CRBU 41.82
- Support Level
- ETON $11.64
- CRBU $1.82
- Resistance Level
- ETON $13.01
- CRBU $1.97
- Average True Range (ATR)
- ETON 0.76
- CRBU 0.14
- MACD
- ETON -0.10
- CRBU -0.02
- Stochastic Oscillator
- ETON 50.43
- CRBU 14.29
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.